MRNA
ModernaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The post-earnings bull read is that Q1 showed real top-line recovery, driven by international COVID sales and new European approvals, while R&D and SG&A both declined year over year and management reiterated 2026 growth and cost-discipline targets [#8-K-2026-05-01].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -2.7.
What can break
A $950 million settlement payment is expected in Q3 2026, creating a real cash outflow after the Q1 non-cash litigation charge [#8-K-2026-05-01].
Momentum
94
Value
41
Sentiment
20
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $43.00 · Bull $58.00 · Bear $30.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $52.16
Why
Momentum94 · Δ7d -2.7
Value41 · Δ7d +0.0
Sentiment20 · Δ7d +4.9
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
94
26% active weight
Current posture
7d trendSoftening
Δ7d
-2.7
Δ21d
+0.1
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
20
34% active weight
Current posture
7d trendImproving
Δ7d
+4.9
Δ21d
+4.1
Why this grade
Composite grade D. Momentum 94.3 / Value 41.1 / Sentiment 20.1
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$23.6B
Beta
1.31
Shares Out
396.79M
P/E (TTM) · Derived
-8.2
P/S (TTM)
5.63
P/FCF (TTM) · Derived
-14.47
Rev YoY
+260.2%
EPS YoY
+35.2%
Gross Margin
+11.6%
Op Margin
-155.2%
Net Debt
-$4.5B
Current Ratio
2.41
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology